Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

Fulvestrant 63Letrozole 53Paclitaxel 49Trastuzumab 41pembrolizumab 40ribociclib 37Specimen Handling 37palbociclib 36Capecitabine 34Carboplatin 33Anastrozole 33Tamoxifen 32exemestane 29pertuzumab 28abemaciclib 28Magnetic Resonance Spectroscopy 26Cyclophosphamide 26trastuzumab deruxtecan 24Surveys and Questionnaires 21Radiotherapy 18Biopsy 18olaparib 17Standard of Care 16Docetaxel 16Blood Specimen Collection 16Taxes 14Mastectomy, Segmental 14eribulin 13elacestrant 13130-nm albumin-bound paclitaxel 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Estradiol × 90 days × Clear all
NCT03941730 2026-05-12

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
8 enrolled 9 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05716516 2026-05-05

ESTHER

Dartmouth-Hitchcock Medical Center

Phase 2 Recruiting
36 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡